pharma news today obesity drugs glp-1 october 2025 Agonists Weight Loss Market Report, 2025-2030 The outlook for obesity from

As of April 2025, the FDA received over 1,000 adverse event reports related to compounded semaglutide and tirzepatide

Broader Applications of GLP-1 Medications GLP-1 medications arent just about weight management they also contribute to better cardiovascular health

After the Four Corners investigation, the TGA reiterated that unapproved peptide products posed serious risks to and those unlawfully advertising, importing, manufacturing or supplying them could face serious legal consequences

(2025) 22:e202402141

Yet, some procarcinogens require phase I enzymes in order to become active carcinogens capable of binding DNA and forming cancer-causing DNA adducts

Why Choose Eskag Pharma for Liposomal Glutathione Supplement Manufacturing